Abstract 92P
Background
Nutrition and immune status are two important factors that affect the occurrence and prognosis of tumors. Evaluating the nutritional and immune status of patients before treatment plays an important role in guiding the development of treatment plans and predicting treatment tolerance. In view of this, this study investigated the nutritional and immune status (BMI, PNI, and lymphocyte subset (NKTB) typing and absolute count) of nasopharyngeal carcinoma patients before treatment, and compared them with the nutritional and immune status of healthy individuals undergoing physical examinations, hoping to provide reference for the assessment of nutritional and immune status of nasopharyngeal carcinoma patients before treatment.
Methods
The study investigated the pretreatment nutritional and immune status (BMI, PNI, and percentage and absolute count of lymphocyte subpopulation) of 201 Newly diagnosed NPC cases and 332 age-sex-matched healthy controls.
Results
PNI was lower in patients with NPC than in healthy controls in both sexes and at different age groups (P < 0.001). Healthy controls had higher BMI than those with NPC (P < 0.005), but there was no difference across the age subgroups. In the NPC group, the absolute numbers of LYM, ALB, and TBNK (CD3+, CD3+CD4+, CD3+ CD8 +, CD16+CD56+, and CD19+) cell subsets were lower than those in the healthy control group (P < 0.001). A comparison of lymphocyte subpopulations in nasopharyngeal carcinomas at different stages revealed that CD3+CD8+(%) in N3 patients was higher than in N0-2. Patients who acquired metastases had higher CD19+ (%). The multifactorial combination index for the differential diagnosis of NPC, which included PNI, EBV, and immunological status, had a sensitivity of 81.59% and specificity of 96.08%.
Conclusions
The nutritional and immune statuses of NPC patients were reduced prior to treatment, and the evaluation of nutritional and immune statuses prior to treatment of patients with NPC at the time of diagnosis is of guiding significance for subsequent anti-tumor treatment, which is worth promoting and applying in the clinic.
Legal entity responsible for the study
The authors.
Funding
Sichuan Science and Technology Program (2023NSFSC1446).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - Anti-CTLA4 therapy leads to early expansion of peripheral Th17 population and induction of Th1 cytokines
Presenter: Mari Nakazawa
Session: Poster Display session
Resources:
Abstract
196P - Single-cell analysis of stage-I high-grade serous ovarian carcinoma reveals the essential role of regulatory T cells in early tumor establishment
Presenter: Joanna Mikulak
Session: Poster Display session
Resources:
Abstract
197P - Comprehensive immunoprofiling of the intratumoral and peripheral T cell receptor gene repertoire in triple-negative breast cancer patients
Presenter: Antonios Mingos
Session: Poster Display session
Resources:
Abstract
198P - Association of types of treatment modalities with expression of T Lymphocytes (CD4, CD8, Treg) in breast cancer patients and their clinical outcome
Presenter: Arshi Rizwan
Session: Poster Display session
Resources:
Abstract
199P - Cancer neutrophil encyclopedia: A deep dive into antigen-presenting warriors
Presenter: Yingcheng Wu
Session: Poster Display session
Resources:
Abstract
200P - CXCR1+ neutrophil infiltration orchestrates response to third-generation EGFR-TKI in EGFR mutant NSCLC
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
201P - Underlying mechanisms of neutrophil-mediated immunosuppression and resistance to treatment in breast cancer: Further evidence that these cells matter
Presenter: Bruna Filipa Correia
Session: Poster Display session
Resources:
Abstract
202P - Mining tumor infiltrating B cells to discover antibody-target pairs and develop novel therapies
Presenter: Matthieu Delince
Session: Poster Display session
Resources:
Abstract
203P - Targeting IL-33 reprograms tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
Presenter: Xuyao Zhang
Session: Poster Display session
Resources:
Abstract
204P - Deciphering the crosstalk between tumor and circulating immune microenvironment in advanced NSCLC patients undergoing immunotherapy
Presenter: Prisca Tamarozzi
Session: Poster Display session
Resources:
Abstract